View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
December 6, 2016

BTG launches DC Bead LUMI for liver cancer patients in Canada

BTG International has launched a next-generation treatment option, DC Bead LUMI, for cancer patients in Canada, marking its first worldwide market commercialisation.

BTG International has launched a next-generation treatment option, DC Bead LUMI, for cancer patients in Canada, marking its first worldwide market commercialisation.

Based on the technology platform of the company’s DC Bead, the DC Bead LUMI is a radiopaque embolic drug-eluting bead that can be loaded with the chemotherapy drug doxorubicin to treat hepatocellular carcinoma (HCC), a commonly occurring primary liver cancer.

It can also be loaded with another chemotherapy drug, irinotecan, to treat malignant colorectal cancer metastasised to the liver (mCRC).

Drug-eluting beads are used in trans-arterial chemoembolisation (TACE), a minimally invasive liver cancer treatment that deliberately blocks blood supply to the tumour and locally delivers a controlled, sustained dose of chemotherapy directly to the tumour.

"The LUMI TACE beads really delivered. They were what one hoped for, so it was easy to see under fluoroscopy, single shot and cone beam CT."

The DC Bead LUMI aids in optimising patient treatment by enabling real-time visible confirmation of bead location during and after the embolisation procedure.

This allows interventional radiologists to have more control simultaneously discovering under-treatment regions, thereby allowing precise evaluation of the completeness of tumour treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.

The treatment option was first performed by Sunnybrook Health Sciences Centre in Canada.

Sunnybrook Health Sciences Centre vascular / interventional radiologist staff Dr Chris Dey said: “The LUMI TACE beads really delivered. They were what one hoped for, so it was easy to see under fluoroscopy, single shot and cone beam CT.

“You can appreciate actual bead deposition in the liver for the first time, flow patterns much more reliably and make intra-procedural adjustments or determine end points more precisely.”

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU